Market Overview

UPDATE: Stifel Nicolaus Raises PT to $83 on Mednax Post Investor Day

Share:
Related MD
US Stock Futures Edge Lower Ahead Of ADP Report
MEDNAX Announces Acquisition of Pediatric Ear, Nose and Throat Practice in Houston
Is Humana (HUM) Likely to Miss Earnings This Season? - Analyst Blog (Zacks)

Stifel Nicolaus reiterated its Buy rating on Mednax (NYSE: MD) and raised its price target from $74 to $83.

Stifel Nicolaus noted, "MEDNAX demonstrated strong top-line and margin growth prospects for its American Anesthesiology division at its investor day. We are raising our target price to reflect this growth as well as pending increases to Medicaid payments to neonatologists. … We came away impressed by both the division's prospects for consolidating the anesthesiology specialty and the potential for improving affiliated practices' financial performance through the rollout of its proprietary clinical software."

Mednax closed at $75.63 on Wednesday.

Latest Ratings for MD

DateFirmActionFromTo
May 2015Raymond JamesMaintainsOutperform
Feb 2015Stifel NicolausUpgradesHoldBuy
Jan 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for MD
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (MD)

Get Benzinga's Newsletters